Related Experiment Videos
[Platelet antiaggregants in cerebral ischemic pathology]
Insights
Platelet aggregation inhibitors like aspirin and ticlopidine effectively prevent secondary strokes from atherosclerosis. However, their role in primary stroke prevention or acute treatment remains unproven.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Context:
- Cerebral ischemia prevention strategies are crucial for reducing stroke incidence.
- Platelet aggregation inhibitors are a primary focus in managing cerebrovascular diseases.
- Atherosclerosis and cardiac conditions like atrial fibrillation are key risk factors for stroke.
Purpose:
- To review the efficacy of platelet aggregation inhibitors in preventing cerebral ischemia.
- To evaluate the current evidence for aspirin and ticlopidine in secondary stroke prevention.
- To discuss the limitations and ongoing research regarding primary stroke prevention and acute treatment.
Summary:
- Aspirin (300 mg/day) and ticlopidine (500 mg/day) demonstrate significant risk reduction (20% and 30% respectively) in secondary prevention of atherosclerotic cerebral ischemic events.
- Current evidence does not support the use of these agents for primary prevention or acute treatment of cerebral infarction.
- Anticoagulants are recommended for preventing thromboembolic stroke of cardiac origin, with ongoing studies assessing aspirin's role in non-valvular atrial fibrillation.
Impact:
- Provides a clear overview of established and emerging therapeutic strategies for cerebral ischemia.
- Highlights the importance of differentiating between primary and secondary stroke prevention.
- Informs clinical practice regarding the appropriate use of antiplatelet agents and anticoagulants in stroke prevention.
Abstract:
Platelet aggregation inhibitors have been more extensively and better studied than all other treatments used in the prevention of cerebral ischaemia. It has been demonstrated that both aspirin (300 mg/day) and ticlopidine (500 mg/day) are effective in the secondary prevention of cerebral ischaemic accidents associated with atherosclerosis, with a 20 and 30 p. 100 respectively reduction of risk. At the moment, there is no evidence that these compounds are effective in the primary prevention or treatment of cerebral infarction in the acute phase. The best way of preventing thromboembolic stroke of cardiac origin is to treat the responsible heart disease and prescribe anticoagulants. However, several studies are in progress to evaluate the effectiveness of aspirin in the primary and secondary prevention of cerebral thromboembolism due to non-valvular atrial fibrillation.